Not Yet RecruitingPhase 3ACTRN12605000681651
Long Term Immunogenicity of the JE Vaccine IC51
Long Term Immunogenicity of the Japanese Encephalitis Vaccine IC51 (JE-PIV).
Sponsor
Intercell AG
Enrollment
600 participants
Start Date
Oct 12, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Plain Language Summary
Simplified for easier understanding
This study looks at the long-term immune response to a Japanese encephalitis vaccine called IC51. Healthy adults aged 18 and older may be eligible. Participants would have blood tests taken at various time points after vaccination to measure how long the immune protection lasts.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A Phase III follow-up study to assess long term safety 6 months after the first vacccination with IC51 and to assess in a subgroup the long term immunogenicity up to 24 months
A Phase III follow-up study to assess long term safety 6 months after the first vacccination with IC51 and to assess in a subgroup the long term immunogenicity up to 24 months
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000681651